|
Gene: TTC7A |
Gene summary for TTC7A |
Gene summary. |
Gene information | Species | Human | Gene symbol | TTC7A | Gene ID | 57217 |
Gene name | tetratricopeptide repeat domain 7A | |
Gene Alias | GIDID | |
Cytomap | 2p21 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q9ULT0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57217 | TTC7A | CCI_1 | Human | Cervix | CC | 3.65e-06 | 6.64e-01 | 0.528 |
57217 | TTC7A | CCI_2 | Human | Cervix | CC | 2.45e-05 | 7.58e-01 | 0.5249 |
57217 | TTC7A | CCI_3 | Human | Cervix | CC | 7.00e-06 | 6.29e-01 | 0.516 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Cervix | CC: Cervix cancer | |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
N_HPV: HPV-infected normal cervix |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
GO:00550726 | Cervix | CC | iron ion homeostasis | 19/2311 | 85/18723 | 6.88e-03 | 3.74e-02 | 19 |
GO:00550768 | Cervix | CC | transition metal ion homeostasis | 27/2311 | 138/18723 | 9.89e-03 | 4.85e-02 | 27 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TTC7A | deletion | In_Frame_Del | c.2593_2604delNNNNNNNNNNNN | p.Glu865_Ala868del | p.E865_A868del | Q9ULT0 | protein_coding | TCGA-44-6147-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
TTC7A | SNV | Missense_Mutation | novel | c.683N>A | p.Gly228Asp | p.G228D | Q9ULT0 | protein_coding | deleterious(0.01) | benign(0.43) | TCGA-CN-A63U-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TTC7A | SNV | Missense_Mutation | novel | c.2187G>T | p.Gln729His | p.Q729H | Q9ULT0 | protein_coding | tolerated(0.74) | possibly_damaging(0.781) | TCGA-CV-6441-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
TTC7A | SNV | Missense_Mutation | rs532590528 | c.2096N>A | p.Arg699Gln | p.R699Q | Q9ULT0 | protein_coding | tolerated(0.32) | benign(0) | TCGA-V1-A8MU-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Hormone Therapy | lhrh | SD |
TTC7A | SNV | Missense_Mutation | novel | c.920N>A | p.Pro307His | p.P307H | Q9ULT0 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
TTC7A | SNV | Missense_Mutation | c.520C>A | p.Leu174Ile | p.L174I | Q9ULT0 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-BR-4370-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTC7A | SNV | Missense_Mutation | c.2361N>T | p.Glu787Asp | p.E787D | Q9ULT0 | protein_coding | tolerated(0.18) | possibly_damaging(0.791) | TCGA-CD-8536-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | epirubicin | CR | |
TTC7A | SNV | Missense_Mutation | rs199788952 | c.1487N>T | p.Thr496Ile | p.T496I | Q9ULT0 | protein_coding | tolerated(0.08) | benign(0.109) | TCGA-D7-A6EZ-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
TTC7A | SNV | Missense_Mutation | c.814N>A | p.Glu272Lys | p.E272K | Q9ULT0 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-F1-6177-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TTC7A | SNV | Missense_Mutation | c.1286N>G | p.Lys429Arg | p.K429R | Q9ULT0 | protein_coding | deleterious(0.05) | probably_damaging(0.996) | TCGA-HF-7132-01 | Stomach | stomach adenocarcinoma | Male | Unknown | I/II | Chemotherapy | fluorouracil | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |